Nurami has closed a Series B Round Led by a Strategic Investor

Nurami Medical is excited to announce the successful completion of its Series B funding round, led by a strong, new strategic investor, the EIC Fund, and many of our current shareholders. This round will support clinical testing of ArtiFix, our adhesive dural patch and in production scale up, to support ongoing commercialization efforts of ArtiFascia, our FDA cleared, multi-layered and versatile dura graft.